Prevalence of Perimyocarditis After Covid-19 Vaccine

Hillel Yaffe Medical Center

Status: Unknown

Conditions: Perimyocarditis; Covid19

Treatments: Diagnostic Test: Antibody test; Diagnostic Test: ECG; Diagnostic Test: PCR; Diagnostic Test: Laboratory Blood Tests; Diagnostic Test: MRI; Diagnostic Test: Echocardiography

Study type: Observational

Funder types: Other

Identifiers

NCT04865900

HYMC-0046-21

Details and patient eligibility

About

The aim of this study is to determine whether there is a higher prevalence of perimyocarditis after undergoing vaccination for Covid-19.

Enrollment: 500 estimated patients

Sex: All

Ages: 16 to 60 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients planning Pfizer-BioNTech BNT162b2 vaccination against Covid19

Exclusion criteria

• Patients infected with Covid19

Trial design

500 participants in 1 patient group

Covid19 Vaccinated Patients

Description:

Patients who are planning to receive Pfizer-BioNTech BNT162b2 vaccines against Covid19

Treatment:

Diagnostic Test: Antibody test

Diagnostic Test: ECG

Diagnostic Test: Laboratory Blood Tests

Diagnostic Test: MRI

Diagnostic Test: PCR

Diagnostic Test: Echocardiography